ANNX
AnnexonBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
ANNX has a real 2026 catalyst stack: ARCHER II topline data, FORWARD-derived U.S./EU package progression in GBS, and ANX1502 proof-of-concept progress, while current cash is guided into 2H27 [#IR-2026-03-30] [#10-K-2026-03-30].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -4.1.
What can break
ARCHER II Phase 3 failure or ambiguous efficacy signal in GA
Momentum
70
Value
41
Sentiment
62
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $6.50 · Bull $11.00 · Bear $3.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-16 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $15.11
Why
Momentum70 · Δ7d +11.7
Value41 · Δ7d -0.1
Sentiment62 · Δ7d -4.1
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
70
26% active weight
Current posture
7d trendImproving
Δ7d
+11.7
Δ21d
+37.2
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
62
34% active weight
Current posture
7d trendSoftening
Δ7d
-4.1
Δ21d
-8.5
Why this grade
Composite grade B. Momentum 70.2 / Value 41.1 / Sentiment 62.0
Fundamentals (TTM)As of 2026-07-16
Fundamentals (TTM)
As of 2026-07-16
Market Cap
$965.03M
Beta
1.17
Shares Out
163.84M
P/E (TTM) · Derived
-4.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-5.30
Rev YoY
-
EPS YoY
-38.1%
Gross Margin
-
Op Margin
-
Net Debt
-$212.14M
Current Ratio
6.35
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology